Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE 0.0%. (2002–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $5M | $41M | $64M | $252M | $1.1B | $1.0B | $546M | $594M | $405M | $600M |
| Enterprise Value | $5M | $8M | $44M | $67M | $259M | $1.1B | $1.0B | $552M | $600M | $413M | $608M |
| P/E Ratio → | -0.98 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.56 | 1.25 | 8.98 | 9.15 | 31.14 | 115.44 | 94.62 | 50.00 | 48.15 | 30.65 | 38.51 |
| P/B Ratio | 0.00 | 0.00 | 5.25 | 8.60 | 58.82 | 184.97 | 128.46 | 59.12 | 19.66 | 9.40 | 10.18 |
| P/FCF | 209.83 | 471.58 | — | — | — | — | — | 1156.38 | 492.34 | 574.70 | 221.91 |
| P/OCF | 15.58 | 35.02 | — | — | — | — | — | 897.85 | 472.31 | 481.46 | 207.09 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.97 | 9.64 | 9.60 | 31.97 | 116.23 | 95.22 | 50.51 | 48.68 | 31.25 | 39.06 |
| EV / EBITDA | — | — | — | 36715.78 | — | 4930.39 | 10226.56 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 740.80 | — | — | — | — | — | 1168.13 | 497.84 | 585.92 | 225.06 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -3.2% | -3.2% | -43.8% | -4.0% | -6.1% | 3.6% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% |
| Operating Margin | -74.5% | -74.5% | -101.3% | -39.2% | -43.8% | -29.7% | -23.7% | -31.0% | -32.2% | -34.0% | -26.9% |
| Net Profit Margin | -76.9% | -76.9% | -104.6% | -43.9% | -49.0% | -35.3% | -26.4% | -189.5% | -87.2% | -145.9% | -59.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.0% | 0.0% | -62.3% | -52.4% | -77.1% | -48.5% | -33.3% | -105.0% | -29.3% | -37.8% | -14.0% |
| ROA | 0.0% | 0.0% | -30.2% | -18.0% | -19.7% | -15.5% | -13.2% | -61.2% | -20.4% | -27.8% | -10.5% |
| ROIC | 0.0% | 0.0% | -32.2% | -19.0% | -21.6% | -15.3% | -13.2% | -9.9% | -6.8% | -5.7% | -4.2% |
| ROCE | 0.0% | 0.0% | -47.0% | -37.5% | -41.3% | -26.2% | -23.5% | -14.3% | -9.2% | -7.6% | -5.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.46 | 0.62 | 2.04 | 2.08 | 0.93 | 0.72 | 0.26 | 0.23 | 0.19 |
| Debt / EBITDA | — | — | — | 2526.73 | — | 54.94 | 73.42 | — | — | — | — |
| Net Debt / Equity | — | 0.00 | 0.38 | 0.43 | 1.57 | 1.27 | 0.81 | 0.60 | 0.22 | 0.18 | 0.14 |
| Net Debt / EBITDA | — | — | — | 1750.37 | — | 33.56 | 63.95 | — | — | — | — |
| Debt / FCF | — | 269.22 | — | — | — | — | — | 11.74 | 5.50 | 11.21 | 3.15 |
| Interest Coverage | -30.24 | -30.24 | -29.73 | -8.23 | -8.14 | -5.27 | -8.75 | -63.35 | -23.07 | -34.52 | -9.45 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.32 | 0.32 | 0.65 | 0.88 | 0.47 | 0.86 | 0.47 | 0.56 | 0.87 | 1.33 | 1.68 |
| Quick Ratio | 0.10 | 0.10 | 0.20 | 0.33 | 0.24 | 0.55 | 0.14 | 0.20 | 0.37 | 0.64 | 0.98 |
| Cash Ratio | 0.00 | 0.00 | 0.12 | 0.21 | 0.16 | 0.46 | 0.08 | 0.11 | 0.12 | 0.22 | 0.26 |
| Asset Turnover | — | 0.00 | 0.30 | 0.43 | 0.46 | 0.43 | 0.51 | 0.49 | 0.27 | 0.22 | 0.20 |
| Inventory Turnover | 0.00 | 0.00 | 2.87 | 1.95 | 2.92 | 2.78 | 2.41 | 2.63 | 2.05 | 1.68 | 1.69 |
| Days Sales Outstanding | — | 25.60 | 22.65 | 37.91 | 20.92 | 31.62 | 17.79 | 22.79 | 32.18 | 67.85 | 99.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.5% | 0.2% | — | — | — | — | — | 0.1% | 0.2% | 0.2% | 0.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $17M | $11M | $5M | $5M | $5M | $5M | $5M | $5M | $5M |
Imminent liquidity and solvency
According to recent financial filings, CPHI's gross margin has deteriorated to -54.9% in 2026Q1, reflecting a fundamental inability to cover production costs that suggests the company's core pharmaceutical manufacturing operations are currently generating negative economic value with every unit sold in the competitive Chinese generic market.
The persistent negative gross margins indicate that the company's cost of goods sold is structurally misaligned with the pricing environment dictated by state procurement policies. This suggests that the firm lacks the scale or manufacturing efficiency required to compete, rendering traditional profitability analysis largely moot as the business model appears to be in a state of terminal decline.
Based on reported figures, the company's asset turnover has effectively stalled at 0.00, while the cash conversion cycle remains distorted by extreme inventory days, signaling that the firm's massive sales infrastructure is failing to translate into meaningful revenue generation or efficient management of its working capital assets.
The disconnect between the 1,000-person sales force and the minimal revenue output suggests a severe lack of operational leverage. Investors should monitor whether the company can rationalize its overhead, as the current utilization of assets appears insufficient to support the ongoing maintenance of its regional distribution network.
As reported in recent quarterly statements, CPHI's current ratio has plummeted to 0.28, a level that underscores an acute liquidity crisis and suggests the company may struggle to meet its short-term obligations without immediate external capital or a drastic, and unlikely, improvement in its operational cash flow.
The quick ratio of 0.07 further highlights the company's reliance on inventory that may be difficult to liquidate at cost, given the ongoing pricing pressures in the generic drug sector. This precarious position warrants extreme caution, as the firm appears to have exhausted its internal financial flexibility.
Investors frequently misapply P/S or P/B multiples to CPHI, which obscures the reality that the company's negative gross margins and dwindling cash reserves render standard valuation metrics irrelevant for a business that may no longer be a viable going concern in its current operational form.
Using traditional valuation ratios assumes a baseline of operational continuity that is not supported by the company's financial trajectory. Instead of P/S, analysts should focus on the cash-to-burn ratio and the sustainability of the current cost structure, as these metrics provide a more accurate assessment of the firm's remaining runway.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CPHI stock.
China Pharma Holdings, Inc.'s current P/E ratio is -1.0x. The historical average is 100.3x.
China Pharma Holdings, Inc.'s return on equity (ROE) is 0.0%. The historical average is -12.1%.
Based on historical data, China Pharma Holdings, Inc. is trading at a P/E of -1.0x. Compare with industry peers and growth rates for a complete picture.
China Pharma Holdings, Inc. has -3.2% gross margin and -74.5% operating margin.